Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
OneSight and WHO Partner on SPECS 2030
The OneSight EssilorLuxottica Foundation has entered a strategic partnership with the World Health Organization (WHO) as a global collaborator in the SPECS 2030 initiative. This alliance aims to expedite progress toward achieving the first global target for effective refractive error…
Global Myopia Surge in Children Predicted to Hit 740M by 2050
A new analysis published in the British Journal of Ophthalmology reveals that nearly one in three children and teens worldwide is expected to be affected by myopia by 2050, translating to over 740 million cases. This trend reflects a significant…
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
ARPA-H Grants $125M for Eye Transplants
The Advanced Research Projects Agency for Health (ARPA-H) has announced funding of up to $125 million to support groundbreaking research into human eye transplantation. The funding, part of the Transplantation of Human Eye Allografts (THEA) program, aims to advance the…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
EPOMEC 2024: Ophthalmology Conference Highlights
The Evolving Practice of Ophthalmology Middle East Conference (EPOMEC) is set to take place from December 5–7, 2024, at the Dubai World Trade Centre, United Arab Emirates. This prestigious event brings together the latest advancements in ophthalmology from across the…
Vision-restoring whole eye transplants may soon be a reality – Stanford Medicine
Vision-restoring whole eye transplants may soon be a reality Stanford Medicine Source: Author: | Date: 2024-12-02 21:30:00 Source: Author: | Date: 2024-12-02 21:30:00